Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes

NCT04020445 · Completed

Last updated 2026-05-28

This clinical trial is testing whether simplifying complex insulin treatment plans can help people with type 2 diabetes maintain good blood sugar control without increasing side effects.

Status Completed The study has finished.

Type Observational

Participants 150 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-01 · est. completion 2022-01

Where 1 site · Hungary

What this study is testing ClinicalTrials.gov NCT04020445 ↗

Description as written by the study sponsor.

This study examines prospectively the safety and efficacy of switching from multiple daily insulin injections (MDI) to once daily IDegLira (insulin degludec and liraglutide fix ratio combination), a fixed-ratio combination of insulin degludec and liraglutide, in relatively well controlled (HbA1c\<7.5%) subjects with type 2 diabetes using low total daily insulin dose (TDD).

Treatments tested

de-escalation of complex insulin regimens Other

complex insulin regimens are switched to fix ratio combinations consisting of of a basal insulin and a GLP-1 (glucagon-like peptide-1) receptor agonist

Main thing measured	Number of participants reaching HbA1c<7% and HbA1c<6.5%
Sponsor	Bekes County Central Hospital
Conditions studied	HBA1c, Body Weight, Hypoglycemia
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04020445 ↗